Therapeutics in Huntington's Disease

被引:12
|
作者
Killoran, Annie [1 ]
Biglan, Kevin M. [1 ]
机构
[1] Univ Rochester, Sch Med & Dent, Movement & Inherited Neurol Disorders Unit, Dept Neurol, Rochester, NY 14620 USA
关键词
Huntington's disease; Huntington disease; Chorea; Treatment; Therapy; Tetrabenazine; Neuroleptics; Haloperidol; Juvenile Huntington's disease; Pharmacologic treatment; Trinucleotide repeat disorder; RANDOMIZED CONTROLLED-TRIAL; MOUSE MODEL; MOTOR; LEVETIRACETAM; RIVASTIGMINE; RISPERIDONE; PROGRESSION; IMPROVEMENT; OLANZAPINE; EFFICACY;
D O I
10.1007/s11940-012-0165-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
There is no specific treatment for Huntington's disease (HD). Its many symptoms of motor, psychiatric, and cognitive deterioration are managed with symptomatic relief, rehabilitation, and support. The only drug approved by the US Food and Drug Administration (FDA) for the treatment of HD is an antichoreic agent, tetrabenazine, but this drug is used sparingly because of uneasiness regarding its propensity to cause depression and suicidality in this population, which is already at risk for these complications. Neuroleptics are still first-line treatments for chorea accompanied by comorbid depression and/or behavioral or psychotic symptoms, as is often the case. Psychiatric features, which have a significant impact on a patient's professional and personal life, often become the major focus of management. In addition to neuroleptics, commonly used medications include antidepressants, mood stabilizers, anxiolytics, and psychostimulants. In contrast, few treatment options are available for cognitive impairment in HD; this remains an important and largely unmet therapeutic need. HD patients typically lack insight into their disease manifestations, failing to recognize their need for treatment, and possibly even arguing against it. Multipurpose medications are employed advantageously to simplify the medication regimen, so as to facilitate compliance and not overwhelm the patient. For example, haloperidol can be prescribed for a patient with chorea, agitation, and anorexia, rather than targeting each symptom with a different drug. This approach also limits the potential for adverse effects, which can be difficult to distinguish from the features of the disease itself. With HD's complexity, it is best managed with a multidisciplinary approach that includes amovement disorders specialist, a genetic counselor, a mental health professional, a physical therapist, and a social worker for support and coordination of services. As the disease progresses, there may be need for other specialists, such as a speech and occupational therapist, a nutritionist for weight loss, and ultimately, a palliative care specialist.
引用
收藏
页码:137 / 149
页数:13
相关论文
共 50 条
  • [21] Implications of Tau Dysregulation in Huntington's Disease and Potential for New Therapeutics
    Mees, Isaline
    Nisbet, Rebecca M.
    Hannan, Anthony J.
    Renoir, Thibault
    [J]. JOURNAL OF HUNTINGTONS DISEASE, 2023, 12 (01) : 1 - 13
  • [22] Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials?
    Bates, GP
    Hockly, E
    [J]. CURRENT OPINION IN NEUROLOGY, 2003, 16 (04) : 465 - 470
  • [23] Designing miRNA Sequences for Huntington Disease Therapeutics
    Monteys, Alejandro Mas
    Spengler, Ryan M.
    Wilson, Matt S.
    Oakley, Clayton K.
    Sowada, Matt J.
    Davidson, Beverly L.
    [J]. MOLECULAR THERAPY, 2014, 22 : S41 - S41
  • [24] Personalized gene silencing therapeutics for Huntington disease
    Kay, C.
    Skotte, N. H.
    Southwell, A. L.
    Hayden, M. R.
    [J]. CLINICAL GENETICS, 2014, 86 (01) : 29 - 36
  • [25] From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research
    Jiang, Andrew
    Handley, Renee R.
    Lehnert, Klaus
    Snell, Russell G.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [26] Selective HDAC class IIa inhibitors as potential therapeutics for Huntington\'s disease
    Burli, Roland
    Dominguez, Celia
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [27] A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease
    Aldous, Sarah G.
    Smith, Edward J.
    Landles, Christian
    Osborne, Georgina F.
    Canibano-Pico, Maria
    Nita, Iulia M.
    Phillips, Jemima
    Zhang, Yongwei
    Jin, Bo
    Hirst, Marissa B.
    Benn, Caroline L.
    Bond, Brian C.
    Edelmann, Winfried
    Greene, Jonathan R.
    Bates, Gillian P.
    [J]. BRAIN, 2024, 147 (05) : 1784 - 1798
  • [28] Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics
    Fienko, Sandra
    Landles, Christian
    Sathasivam, Kirupa
    McAteer, Sean J.
    Milton, Rebecca E.
    Osborne, Georgina F.
    Smith, Edward J.
    Jones, Samuel T.
    Bondulich, Marie K.
    Danby, Emily C. E.
    Phillips, Jemima
    Taxy, Bridget A.
    Kordasiewicz, Holly B.
    Bates, Gillian P.
    [J]. BRAIN, 2022, 145 (12) : 4409 - 4424
  • [29] The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington's Disease
    Bhat, Shahnawaz Ali
    Ahamad, Shakir
    Dar, Nawab John
    Siddique, Yasir Hassan
    Nazir, Aamir
    [J]. CURRENT NEUROPHARMACOLOGY, 2023, 21 (04) : 867 - 889
  • [30] The Emerging Landscape of Small-Molecule Therapeutics for the Treatment of Huntington'S Disease
    Ahamad, Shakir
    Bhat, Shahnawaz A.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2022, : 15993 - 16032